OCULAR THERAPEUTIX, INC Proceeds from Sale and Maturity of Marketable Securities
OCULAR THERAPEUTIX, INC (OCUL) reported Proceeds from Sale and Maturity of Marketable Securities of $54.83 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities · last filed 2016-03-10
- OCULAR THERAPEUTIX, INC proceeds from sale and maturity of marketable securities for fiscal 2015 was $54.83M.
| Period end | Proceeds from Sale and Maturity of Marketable Securities 12 month |
|---|---|
| 2015-12-31 | $54.83M 10-K · filed 2016-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |